In 2009, Themis Bioscience was established by a team of seasoned biotech professionals and immediately attracted several millions of Euro of venture and public capital. Already a year after its foundation, a world-leading European vaccine research institute secured a joint R&D program with us. This highly prestigious partnership venture gave Themis rights on an innovative Measles virus vaccine vector technology that now forms the basis of our Themaxyn® platform.

A clinical trial of our Chikungunya vaccine candidate in 2014 confirmed the use of the platform for vaccine development. This proof-of-concept was published in a highly acclaimed journal in 2015, The Lancet Infectious Diseases. Immediately afterwards, both, significant sums of fresh capital and experienced new members of the board boosted our ongoing expansions plans.